IHS Chemical Week

EnviroTech :: Regulatory

Lonza and Biotech Firm Settle Legal Dispute

4:01 PM MDT | May 5, 2008 | DR

Lonza (Basel, Switzerland) says it has settled a legal dispute with biotechnology company Northwest Biotherapeutics (Bethesda, MD) involving Lonza’s GS Gene Expression System. All claims and counterclaims between the companies are to be dismissed, based on an agreement that Northwest Biotherapeutics will destroy the GS Gene Expression System materials in its possession, Lonza says. The GS Gene Expression System, which is owned and licensed by Lonza, is used to produce therapeutic recombinant proteins and monoclonal antibodies. This system is characterized...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week subscriber yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine a year in print or digital format
  • Real time news and analysis on chemweek.com 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now


contact us | about us | privacy policy | sitemap

ihsCopyright © IHS, Inc.All rights reserved.Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa